Magnetar Financial LLC Takes $389,000 Position in Twist Bioscience Co. (NASDAQ:TWST)

Magnetar Financial LLC bought a new stake in Twist Bioscience Co. (NASDAQ:TWST) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 11,345 shares of the company’s stock, valued at approximately $389,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. EdgeRock Capital LLC bought a new position in Twist Bioscience during the 4th quarter valued at $30,000. Headlands Technologies LLC bought a new position in Twist Bioscience during the 1st quarter valued at $124,000. International Assets Investment Management LLC boosted its stake in Twist Bioscience by 3,519.8% during the 4th quarter. International Assets Investment Management LLC now owns 4,018 shares of the company’s stock valued at $148,000 after acquiring an additional 3,907 shares during the last quarter. Brown Advisory Inc. bought a new position in Twist Bioscience during the 4th quarter valued at $225,000. Finally, Quantbot Technologies LP bought a new position in Twist Bioscience during the 1st quarter valued at $232,000.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, COO Patrick John Finn sold 2,207 shares of the firm’s stock in a transaction dated Tuesday, July 23rd. The shares were sold at an average price of $56.62, for a total transaction of $124,960.34. Following the transaction, the chief operating officer now owns 171,212 shares of the company’s stock, valued at approximately $9,694,023.44. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other news, COO Patrick John Finn sold 2,207 shares of the firm’s stock in a transaction dated Tuesday, July 23rd. The shares were sold at an average price of $56.62, for a total transaction of $124,960.34. Following the completion of the transaction, the chief operating officer now owns 171,212 shares in the company, valued at approximately $9,694,023.44. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Paula Green sold 910 shares of the firm’s stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $37.13, for a total transaction of $33,788.30. Following the transaction, the senior vice president now owns 91,511 shares of the company’s stock, valued at approximately $3,397,803.43. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 19,603 shares of company stock valued at $886,642. Company insiders own 3.92% of the company’s stock.

Twist Bioscience Stock Down 0.9 %

Twist Bioscience stock traded down $0.52 during trading hours on Monday, hitting $57.56. 30,913 shares of the company traded hands, compared to its average volume of 1,021,849. The firm has a market cap of $3.35 billion, a P/E ratio of -17.15 and a beta of 1.80. The firm’s 50-day simple moving average is $49.59 and its two-hundred day simple moving average is $40.80. Twist Bioscience Co. has a 1-year low of $14.42 and a 1-year high of $60.90.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Thursday, May 2nd. The company reported ($0.79) EPS for the quarter, beating the consensus estimate of ($0.84) by $0.05. The firm had revenue of $75.30 million for the quarter, compared to analysts’ expectations of $70.70 million. Twist Bioscience had a negative net margin of 69.24% and a negative return on equity of 31.61%. Twist Bioscience’s quarterly revenue was up 25.1% on a year-over-year basis. During the same quarter last year, the company earned ($1.06) EPS. On average, equities research analysts predict that Twist Bioscience Co. will post -3.08 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Guggenheim assumed coverage on shares of Twist Bioscience in a report on Tuesday, June 4th. They set a “buy” rating and a $53.00 target price on the stock. The Goldman Sachs Group increased their target price on shares of Twist Bioscience from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Tuesday, July 9th. TD Cowen increased their target price on shares of Twist Bioscience from $55.00 to $65.00 and gave the stock a “buy” rating in a report on Thursday, June 13th. Barclays increased their target price on shares of Twist Bioscience from $45.00 to $60.00 and gave the stock an “overweight” rating in a report on Friday, June 28th. Finally, Robert W. Baird increased their target price on shares of Twist Bioscience from $39.00 to $40.00 and gave the stock an “outperform” rating in a report on Friday, May 3rd. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, Twist Bioscience presently has an average rating of “Buy” and an average price target of $49.75.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.